Drug Profile
AGN 323
Alternative Names: AGN-323Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Developer AbbVie
- Class Analgesics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pain in USA
- 04 Dec 2008 Phase-I clinical trials in Pain in USA (unspecified route)